Ana M. Panaite
ampanaite.bsky.social
Ana M. Panaite
@ampanaite.bsky.social
MSCA PhD | Nanomedicine for Oncology Therapy and Diagnosis | Magnetic Nanoparticles, MOFs, Magnetic Hyperthermia, Drug Delivery & MRI/MPI Imaging | Scientific & Clinical data interpretation | Translational Research

Book and art lover📚🖼️🎨
Pinned
Load more. Release on demand.
Our new paper in Small presents ZIF-8 growth onto MNPs enabling ultrahigh drug loading and AMF-triggered release, a smart approach to remotely controlled drug delivery.
doi.org/10.1002/smll...

#MOFs #MagneticNanoparticles #DrugDelivery #WomenInSTEM @iitalk.bsky.social
Seeded‐Growth of ZIF‐8 onto Magnetic Nanoparticles: Smart Nanocarriers with Ultrahigh Drug Loading for AMF‐Triggered Release
We developed core-shell iron oxide@ZIF-8 magnetic-MOF nanohybrids via a seeded growth method for magnetic hyperthermia-triggered drug delivery. Cubic cores and thinner shells maximized heating. In-si....
doi.org
Reposted by Ana M. Panaite
Little red dots may reside in small, dense galaxies with total masses equivalent to around one billion times that of the Sun, according to research in Nature Astronomy. The findings offer new clues about how these mysterious objects developed. go.nature.com/4ca4cIx 🔭🧪
August 24, 2026 at 10:55 PM
Load more. Release on demand.
Our new paper in Small presents ZIF-8 growth onto MNPs enabling ultrahigh drug loading and AMF-triggered release, a smart approach to remotely controlled drug delivery.
doi.org/10.1002/smll...

#MOFs #MagneticNanoparticles #DrugDelivery #WomenInSTEM @iitalk.bsky.social
Seeded‐Growth of ZIF‐8 onto Magnetic Nanoparticles: Smart Nanocarriers with Ultrahigh Drug Loading for AMF‐Triggered Release
We developed core-shell iron oxide@ZIF-8 magnetic-MOF nanohybrids via a seeded growth method for magnetic hyperthermia-triggered drug delivery. Cubic cores and thinner shells maximized heating. In-si....
doi.org
August 24, 2026 at 8:19 AM
Reposted by Ana M. Panaite
Seeded‐Growth of ZIF‐8 onto Magnetic Nanoparticles: Smart Nanocarriers with Ultrahigh Drug Loading for AMF‐Triggered Release https://onlinelibrary.wiley.com/doi/10.1002/smll.74972?af=R
August 11, 2026 at 1:38 PM
Reposted by Ana M. Panaite
Advances in the application of metal–organic frameworks in ophthalmology http://pubs.rsc.org/en/Content/ArticleLanding/2026/BM/D5BM01641J
March 24, 2026 at 1:41 PM
Reposted by Ana M. Panaite
A metal–organic framework Ce-BDA for triple-modal cancer therapy: chemodynamic therapy, chemotherapy and immunotherapy http://pubs.rsc.org/en/Content/ArticleLanding/2026/DT/D6DT00195E
March 27, 2026 at 12:27 PM
Reposted by Ana M. Panaite
Stimuli-responsive, prodrug-activating enzyme-functionalized metal-organic frameworks for cancer therapy and tumor microenvironment modulation https://www.sciencedirect.com/science/article/pii/S0010854526003796
April 10, 2026 at 4:27 PM
Reposted by Ana M. Panaite
Peptide Based Covalent Organic Framework for the Magnetic Resonance Imaging‐Mediated Attenuation of Amyloid‐β Fibrils https://advanced.onlinelibrary.wiley.com/doi/10.1002/adfm.202529220?af=R
April 11, 2026 at 9:23 AM
Reposted by Ana M. Panaite
Metal-organic frameworks for Cuproptosis-based Cancer therapy https://www.sciencedirect.com/science/article/pii/S001085452600411X
April 27, 2026 at 9:57 AM
Reposted by Ana M. Panaite
Metal organic framework and doxorubicin co-encapsulated pH-responsive hydrogels against breast cancer through synergistic therapy http://pubs.rsc.org/en/Content/ArticleLanding/2026/NJ/D6NJ01310D
June 9, 2026 at 7:30 AM
🔥 𝐓𝐡𝐫𝐞𝐞 𝐰𝐚𝐲𝐬 𝐭𝐨 𝐡𝐞𝐚𝐭 𝐚 𝐭𝐮𝐦𝐨𝐫. 𝐎𝐧𝐞 𝐯𝐞𝐫𝐬𝐚𝐭𝐢𝐥𝐞 𝐩𝐥𝐚𝐭𝐟𝐨𝐫𝐦: 𝐌𝐎𝐅𝐬.
Our review in Materials Today explores MOF composites for #microwave, #photothermal, and #magnetic hyperthermia, and how these hybrid materials can enable controlled drug release and multimodal cancer therapy.
📖 Read 👉 lnkd.in/eZcSbRK9
August 21, 2026 at 1:23 PM
Reposted by Ana M. Panaite
Drugging the undruggable: early phase trial shows trabectedin and low-dose irinotecan downregulate EWSR1::FLI1 and has clinical activity in advanced Ewing sarcoma
Drugging the undruggable: early phase trial shows trabectedin and low-dose irinotecan downregulate EWSR1::FLI1 and has clinical activity in advanced Ewing sarcoma
Targeting transcription factor fusion-positive cancers has proven challenging for decades. In SARC037, Grohar et al. show that histology-specific dosing of trabectedin and low-dose irinotecan is active in advanced Ewing sarcoma and downregulates EWSR1::FLI1 activity.
dlvr.it
August 21, 2026 at 12:22 PM
🔥 𝐓𝐡𝐫𝐞𝐞 𝐰𝐚𝐲𝐬 𝐭𝐨 𝐡𝐞𝐚𝐭 𝐚 𝐭𝐮𝐦𝐨𝐫. 𝐎𝐧𝐞 𝐯𝐞𝐫𝐬𝐚𝐭𝐢𝐥𝐞 𝐩𝐥𝐚𝐭𝐟𝐨𝐫𝐦: 𝐌𝐎𝐅𝐬.
Our review in Materials Today explores MOF composites for #microwave, #photothermal, and #magnetic hyperthermia, and how these hybrid materials can enable controlled drug release and multimodal cancer therapy.
📖 Read 👉 lnkd.in/eZcSbRK9
August 18, 2026 at 8:13 AM